Enbrel 50 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FA1GD
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $23,450
Award facts
- Contract value 100% obligated
- $23,449.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $23,449.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML Syringes on January 16, 2026, with an ultimate completion date of January 20, 2026. This non-competitive award was issued without a set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a task order issued under AmerisourceBergen's parent company, Cencora, Inc., which holds a substantial Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2031, serving as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
ENBREL is a biologic immunosuppressant medication used to treat rheumatoid arthritis, psoriatic arthritis, and other autoimmune conditions, making this delivery order part of the Defense Health Agency's broader pharmaceutical supply requirements for military treatment facilities and veteran healthcare systems. The delivery order structure under the larger DLA Troop Support Medical contract demonstrates the flexibility and efficiency of indefinite delivery vehicles in meeting the federal government's ongoing medical supply needs across multiple therapeutic domains. This award reflects AmerisourceBergen's established capability as a critical pharmaceutical distributor within the federal medical procurement ecosystem, with consistent access to competitively awarded contract vehicles for supplying essential medications and medical commodities to Department of Defense and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DR26FA1GD?
SPE2DR26FA1GD was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FA1GD worth?
The government has obligated $23,450 on SPE2DR26FA1GD.
Is contract SPE2DR26FA1GD an order under another contract?
Yes. SPE2DR26FA1GD is a delivery order under SPE2DR25D2100, an indefinite delivery contract.
Was contract SPE2DR26FA1GD competed?
The extent of competition for SPE2DR26FA1GD was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award